These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8106899)

  • 1. In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers.
    Sader HS; Jones RN; Allen SD; Gerlach EH; Murray PR; Washington JA
    J Chemother; 1993 Oct; 5(5):283-8. PubMed ID: 8106899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones.
    Sader HS; Erwin ME; Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):372-81. PubMed ID: 1327789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of CS-940, a new trifluorinated quinolone.
    Biedenbach DJ; Sutton LD; Jones RN
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2325-30. PubMed ID: 8619590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of OPC-17116.
    Neu HC; Fang W; Gu JW; Chin NX
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1310-5. PubMed ID: 1329620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.
    Clement JJ; Tanaka SK; Alder J; Vojtko C; Beyer J; Hensey D; Ramer N; McDaniel D; Chu DT
    Antimicrob Agents Chemother; 1994 May; 38(5):1071-8. PubMed ID: 8067740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissociated resistance among fluoroquinolones.
    Thomson KS; Sanders CC
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2095-100. PubMed ID: 7811025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of CP-74667 compared with four other fluoroquinolones.
    Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1992 Aug; 15(6):531-6. PubMed ID: 1330419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.
    Marshall SA; Jones RN
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2747-53. PubMed ID: 8109948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
    Rotstein C; Amsterdam D; Beam TR; Mandell LA; Gorzynski EA
    Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria.
    Wakebe H; Mitsuhashi S
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2185-91. PubMed ID: 1332589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae.
    Zenilman JM; Neumann T; Patton M; Reichart C
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2244-6. PubMed ID: 8257153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of new quinolones against ciprofloxacin-resistant staphylococci.
    Forstall GJ; Knapp CC; Washington JA
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1679-81. PubMed ID: 1656873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin.
    Mirelis B; Navarro F; Miró E; Coll R; Xicota MA; Prats G
    Drugs Exp Clin Res; 1995; 21(4):129-38. PubMed ID: 8529525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Apr; 31(4):497-504. PubMed ID: 8390433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
    Fung-Tomc J; Minassian B; Kolek B; Washo T; Huczko E; Bonner D
    J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter comparative study of the in vitro activity of fleroxacin and other antimicrobial agents.
    Markowitz SM; Williams DS; Hanna CB; Parker JL; Pierce MA; Steele JC
    Chemotherapy; 1995; 41(6):477-86. PubMed ID: 8529440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.